Dataset Information
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
Ontology highlight
ABSTRACT:
SUBMITTER: Ansari J
PROVIDER: S-EPMC3588609 | biostudies-other | 2013
REPOSITORIES: biostudies-other
Publications
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
Biologics : targets & therapy 20130228
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, ...[more]